EUVIMEDEUVIMED entdecken
Crossref

Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement

Simon N. Bomken, Amir Enshaei, Edward Schwalbe, A Mikulasova, Y Dai, M Zaka, KTM Fung, Matthew Bashton, HK Lim, L Jones, Nefeli Karataraki, E Winterman und 28 weitere

Newcastle University ePrints (Newcastle Univesity) · 01.03.2023

DOI: 10.25405/ncl.34452180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Newcastle University ePrints (Newcastle Univesity), erschienen am 01.03.2023. Verfasst von Simon N. Bomken und 39 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) carries an immunoglobulin-MYC rearrangement (IG-MYC-r). This can result in diagnostic confusion with Burkitt lymphoma/leukaemia and use of unproven individualised treatment schedules. Here we contrast the molecular characteristics of these conditions and investigate historic clinical outcome data.We identified 90 cases registered on a national BCP-ALL clinical trial/registry. Where present, diagnostic material underwent cytogenetic, exome, methylome and transcriptome analysis. Outcome was analysed to define 3-year event free survival (EFS) and overall survival (OS).IG-MYC-r was identified in diverse cytogenetic backgrounds, co-existing with either: established BCP-ALL specific abnormalities (high hyperdiploidy n=3, KMT2A-rearrangement n=6, iAMP21 n=1, BCR-ABL n=1); BCL2/BCL6-rearrangements (n=15); or, most commonly, as the only defining feature (n=64). Within this final group, precursor-like V(D)J breakpoints predominated (8/9) and KRAS mutations were common (5/11). DNA methylation identified a cluster of V(D)J rearranged cases, clearly distinct from Burkitt leukaemia/lymphoma. Children with IG-MYC-r within that subgroup had 3-year EFS of 47% and OS of 60%, representing a high-risk BCP-ALL. To develop effective management strategies this patient group must be allowed access to contemporary, minimal residual disease adapted, prospective clinical trial protocols.

Zitieren

APA

Bomken, S. N., Enshaei, A., Schwalbe, E., Mikulasova, A., Dai, Y., Zaka, M., Fung, K., Bashton, M., Lim, H., Jones, L., Karataraki, N., Winterman, E., Ashby, C., Attarbaschi, A., Bertrand, Y., Bradtke, J., Buldini, B., Burke, G. A., Cazzaniga, G., …, & Russell, L. J. (2023). Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. Newcastle University ePrints (Newcastle Univesity). https://doi.org/10.25405/ncl.34452180

Vancouver

Bomken SN, Enshaei A, Schwalbe E, Mikulasova A, Dai Y, Zaka M, et al. Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. Newcastle University ePrints (Newcastle Univesity). 2023. doi:10.25405/ncl.34452180

BibTeX
@article{Bomken2023,
  author = {Bomken, Simon N. and Enshaei, Amir and Schwalbe, Edward and Mikulasova, A and Dai, Y and Zaka, M and Fung, KTM and Bashton, Matthew and Lim, HK and Jones, L and Karataraki, Nefeli and Winterman, E and Ashby, C and Attarbaschi, A and Bertrand, Y and Bradtke, J and Buldini, B and Burke, G. A.Amos and Cazzaniga, G and Gohring, G and Groot-Kruseman, HA De and Haferlach, C and Nigro, L Lo and Parihar, M and Plesa, A and Seaford, E and Sonneveld, E and Strehl, S and Velden, V van der and Rand, Vikki and Hunger, SP and Harrison, C. M. and Bacon, Chris M. and Delft, Frederik W. van and Loh, M and Moppett, J and Vormoor, J and Walker, BA and Moorman, Anthony V. and Russell, Lisa Jane},
  title = {Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement},
  journal = {Newcastle University ePrints (Newcastle Univesity)},
  year = {2023},
  doi = {10.25405/ncl.34452180}
}
Kostenlos starten →